SNIPR Biome reports positive clinical interim results for groundbreaking, first-in-human, CRISPR-based microbial gene therapy
· SNIPR001 demonstrates proof of principle in reducing E. coli levels in the human gastrointestinal tract · SNIPR001 is a novel CRISPR-Cas therapeutic, selectively targeting antibiotic-resistant E. coli which can cause life-threatening infections in vulnerable hematological cancer patients · Future studies needed to evaluate the impact of SNIPR001 on reducing the rate of E. coli infections in high-risk cancer patientsCopenhagen, May 31, 2023: SNIPR Biome ApS (“SNIPR”), the company pioneering CRISPR-based microbial gene therapy, today announces positive interim clinical results from